The biomakers for ovarian mucinous carcinoma, including the KRAS and HER2-neu genes, MEK, and PI3K, and molecular target drugs such as trastuzumab, lapatinib, and cetuximab have been gaining attention. Here, ERBB2 is linked to ovarian mucinous adenocarcinoma.